Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07113743) titled 'Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease' on Aug. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Condition:
Chronic Granulomatous Disease (CGD)
Intervention:
Drug: Busulfan
Drug: Tocilizumab
Drug: Eltrombopag
Drug: Sirolimus
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: August 27, 2025
Target Sample Size: 10...